Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Enavogliflozin (DWP16001) in Healthy Subjects of Different Ethnicities
NCT05207176Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax), Area Under the Curve to the Last Quantifiable Concentration (AUClast) and 2 more. Status: unknown.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05207176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207176.